Vericel (VCEL) Competitors

Roivant Sciences (NASDAQ:ROIV) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Is ROIV or VCEL more profitable?

Vericel has a net margin of 1.56% compared to Roivant Sciences' net margin of -119.54%. Vericel's return on equity of 1.48% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-119.54%	-14.05%	-12.81%
Vericel	1.56%	1.48%	0.96%

Which has stronger earnings & valuation, ROIV or VCEL?

Roivant Sciences has higher earnings, but lower revenue than Vericel. Roivant Sciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$122.59M	64.26	$4.35B	-$0.15	-73.60
Vericel	$238.54M	9.18	-$3.18M	$0.03	1,450.67

Does the MarketBeat Community prefer ROIV or VCEL?

Vericel received 300 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 61.74% of users gave Vericel an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%
Vericel	Outperform Votes 355 61.74%	Underperform Votes 220 38.26%

Which has more risk & volatility, ROIV or VCEL?

Roivant Sciences has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in ROIV or VCEL?

64.8% of Roivant Sciences shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 5.2% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts rate ROIV or VCEL?

Roivant Sciences currently has a consensus target price of $17.50, suggesting a potential upside of 58.51%. Vericel has a consensus target price of $60.86, suggesting a potential upside of 39.84%. Given Roivant Sciences' higher probable upside, equities analysts clearly believe Roivant Sciences is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Vericel	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor ROIV or VCEL?

In the previous week, Roivant Sciences had 7 more articles in the media than Vericel. MarketBeat recorded 13 mentions for Roivant Sciences and 6 mentions for Vericel. Roivant Sciences' average media sentiment score of 1.44 beat Vericel's score of 1.42 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences and Vericel tied by winning 9 of the 18 factors compared between the two stocks.